Black Linda L, Gaynor James, Adams Cheryl, Dhupa Sarit, Sams Andrew E, Taylor Robert, Harman Susan, Gingerich Daniel A, Harman Robert
Vet-Stem Inc., 12860 Danielson Court, Poway, CA 92064, USA.
Vet Ther. 2008 Fall;9(3):192-200.
Autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy involves harvesting fat from the patient, isolating the stem and regenerative cells, and administering the cells back to the patient. Autologous AD-MSC therapy in veterinary regenerative medicine has been commercially available since 2003. Previously reported results from a blinded, controlled trial in dogs with chronic osteoarthritis of the coxofemoral (hip) joint demonstrated efficacy of a single intraarticular injection of autologous AD-MSC therapy. The primary objective of the current study was to evaluate the effectiveness of this therapy in dogs with chronic osteoarthritis of the humeroradial (elbow) joints and to determine the duration of effect. Fourteen dogs were recruited. Veterinarians assessed each dog for lameness, pain on manipulation, range of motion, and functional disability using a numeric rating scale at baseline and specified intervals up to 180 days after treatment. Statistically significant improvement in outcome measures was demonstrated.
自体脂肪间充质干细胞（AD-MSC）疗法包括从患者身上采集脂肪，分离出干细胞和再生细胞，然后将这些细胞回输到患者体内。自2003年以来，自体AD-MSC疗法在兽医再生医学中已商业化应用。先前一项针对患有髋股（髋关节）关节慢性骨关节炎的犬类进行的双盲对照试验报告结果显示，单次关节内注射自体AD-MSC疗法具有疗效。本研究的主要目的是评估该疗法对患有肱桡（肘关节）关节慢性骨关节炎犬类的有效性，并确定其疗效持续时间。招募了14只犬。兽医在基线时以及治疗后长达180天的特定时间间隔，使用数字评分量表对每只犬的跛行、手法检查时的疼痛、活动范围和功能障碍进行评估。结果显示，各项指标均有统计学意义的改善。
